Veterinary Medicines

Karallact 75 mg ziede ievadīšanai tesmenī laktējošām govīm

Authorised
  • Cefquinome
Download as PDF

Product identification

Medicine name:
Karallact 75 mg ziede ievadīšanai tesmenī laktējošām govīm
Active substance:
  • Cefquinome
Target species:
  • Cattle (lactating cow)
Route of administration:
  • Intramammary use

Product details

Active substance and strength:
  • Cefquinome
    75.00
    milligram(s)
    /
    1.00
    Syringe
Pharmaceutical form:
  • Intramammary ointment
Withdrawal period by route of administration:
  • Intramammary use
    • Cattle (lactating cow)
      • Meat and offal
        2
        day
      • Milk
        84
        hour
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ51DE90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Latvia
Available in:
  • Latvia
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • PVD
Authorisation number:
  • V/NRP/15/0005
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 4/03/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 4/03/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Latvian (PDF)
Published on: 4/03/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."